Welcome to our dedicated page for Immunoprecise news (Ticker: IPA), a resource for investors and traders seeking the latest updates and insights on Immunoprecise stock.
MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd. (IPA), reports developments in Bio-Native AI, biologics discovery, and AI-driven drug development. Company updates focus on the HYFT® technology stack and the LensAI™ platform, which combine computational analysis with wet-lab validation for epitope mapping, de novo molecular design, in silico vaccine exploration, immunogenicity screening, and population-scale biologics analytics.
Recurring news also covers earnings releases, platform commercialization, partnership and customer activity, and portfolio initiatives such as B Cell Llama™ nanobody discovery and dengue vaccine research. Corporate updates include the transition from the ImmunoPrecise brand to MindWalk, the Nasdaq ticker change to HYFT, and portfolio refinements such as the divestiture of the Netherlands antibody-discovery operations.
ImmunoPrecise Antibodies Ltd. (IPA) announced positive results from its IND-enabling safety studies for the PolyTope® TATX-03 antibody cocktail aimed at COVID-19. Conducted under GLP standards, the studies revealed no adverse effects or off-target binding, supporting its safety and potential efficacy. No mortality or organ changes were observed during extensive testing, and cross-reactivity studies confirmed specificity to intended targets. These findings are crucial for clinical study approval, with first-in-human trials expected to begin later this year.
IPA subsidiary BioStrand secures €460,000 grant to enhance its LENSai platform by integrating HYFTs™ with 3D protein structures and functions. This funding, awarded by VLAIO, will support the platform's expansion to improve protein structure predictions, particularly for antibodies and GPCRs. BioStrand aims to provide a comprehensive AI Discovery platform, enhancing data analysis capabilities in biotechnology and precision medicine. Additionally, the company announces the immediate departure of Chief Business Officer Stefan Lang, effective immediately.
IPA announced encouraging results from its PolyTope® TATX-03 antibody cocktail, demonstrating effective neutralization against the Omicron sublineage BA.2. The data showed that the neutralization potency against BA.2 is comparable to BA.1.
All therapeutic antibodies in the cocktail maintained their reactivity to the BA.2 spike protein, reinforcing the product's consistency against SARS-CoV-2 variants.
Dr. Ilse Roodink emphasized the sustained efficacy of TATX-03 against evolving viral mutants, underlining its potential significance in combating COVID-19 variants.
ImmunoPrecise Antibodies has successfully completed its acquisition of BioStrand BV, BioKey BV, and BioClue BV, enhancing its capabilities in bioinformatics and biotechnology. This strategic move, valued at approximately €20 million, aims to leverage AI and machine learning technologies to innovate biotherapeutic discovery processes. The deal includes a combination of common shares and cash, as well as a potential earnout based on BioStrand's future profitability. The integration is expected to significantly improve personalized medicine development.
ImmunoPrecise Antibodies (IPA) has signed a share purchase agreement to acquire BioStrand, BioKey, and BioClue for a total of €20 million, with €2 million in cash and €18 million in equity. This acquisition enhances IPA's capabilities in bioinformatics and biotechnology through its proprietary HYFT patterns, which improve data analysis in multi-omics research. The transaction is expected to attract new clients and support IPA's Talem Therapeutics in antibody development. The deal received unanimous approval and is projected to close by April 15, 2022.
ImmunoPrecise Antibodies Ltd. (IPA) reported its Q3 fiscal 2022 results, achieving project revenue of $4.1 million, a rise of 22.6% year-over-year. Total revenue increased to $4.8 million, up 6.6%. The company invested $1.8 million in R&D, significantly higher than last year. However, it recorded a net loss of $3.8 million, worsening from a $1.3 million loss a year ago. As of January 31, 2022, cash reserves stood at $33.0 million.
IPA and Elektrofi are collaborating to develop a low-volume injectable formulation, TATX-03E, of IPA's COVID-19 antibody cocktail, PolyTope® TATX-03. This self-administered formulation aims to provide a stable and easily distributed option for immunodeficient patients requiring ongoing therapy. The collaboration will utilize Elektrofi's technology to enhance delivery methods, supported by a contract from the Department of Defense. The initiative seeks to establish safety and efficacy through IND-enabling studies, with a focus on meeting patient needs and improving access to critical therapies.
ImmunoPrecise Antibodies (NASDAQ: IPA) has partnered with Elektrofi to develop a low-volume self-injectable formulation of its COVID-19 antibody cocktail, PolyTope® TATX-03, now referred to as TATX-03E. This innovative formulation targets immunocompromised patients who require ongoing treatment, allowing for easier at-home administration. Supported by the Department of Defense's SBIR Program, the collaboration will focus on creating an IND-enabling data package for FDA approval, enhancing access to vital therapies for COVID-19 and similar conditions.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) reports encouraging results from its latest studies on the PolyTope® TATX-03 antibody cocktail for SARS-CoV-2.
- Animal tests show no acute adverse events, indicating a strong safety profile.
- No pharmacokinetic aberrations were observed.
- Maximum tolerated dose studies revealed no toxicity even at 12.5 times the proposed human dose.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) announced a conference call scheduled for March 16, 2022, at 10:30 a.m. ET, to discuss its third quarter fiscal year 2022 financial results and recent business highlights. The company will issue a press release before the call, and management will host a question-and-answer session. Investors can submit their questions to John Mullaly of LifeSci Advisors. The call will be available via webcast and can be accessed from the company's investor relations website.